# US 11,439,638 B1 · Drug and diagnostic combination system to identify and treat single-stranded RNA viruses including coronaviruses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,439,638 B1 - Document ID: US11439638B1 - Status: Granted - Kind: B1 - Application number: 17/565,675 - Filed: 2021-12-30 - Granted: 2022-09-13 - Earliest claimed: 2021-10-06 - Assignees: Feynman Labs, LLC - Applicants: AiPharma Global Holdings LLC - Inventors: Carl Johan Freer; Richard Kaszynski; Alessandro Gadotti - Web page: https://patentgrep.com/patent/US11439638B1 ## CPC - A61K 31/4965: Non-condensed pyrazines - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - A61P 31/14: for RNA viruses - G01N 33/54388: {based on lateral flow} - G01N 33/56983: {Viruses} - G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) ## Abstract A method for treating an early-stage microbial infection comprising determining whether a subject exposed to a coronavirus, such as SARS-CoV-2, or suspected of being exposed to a microbe, or exposed to another infected with or suspected of being infected with a coronavirus and, if the subject is infected with the coronavirus, administering an antimicrobial agent is provided herein. ## Claims ### Claim 1 A method for treating an early-stage infection by a virus in a subject comprising the steps of: obtaining a sample from the subject, providing the sample to a lateral flow assay, determining whether the subject is infected with the virus based on the results of the lateral flow assay, and if the subject is determined to be infected with the virus, administering to an antiviral agent and an antiparasitic agent the subject, wherein the subject has been exposed to the virus, is suspected of having been exposed to the virus, or has been in contact with a person exposed to or suspected of being exposed to the virus, wherein the antiviral agent is selected from the group consisting of favipiravir, favipiravir-RTP, remdesivir, and molnupiravir and the antiparasitic agent is ivermectin, and wherein the virus is SARS-CoV-2. ### Claim 2 (depends on 1) The method of claim 1, wherein the antiviral agent is favipiravir. ### Claim 3 (depends on 2) The method of claim 2, wherein the favipiravir is administered at a dose of between about 1600 mg and about 1800 mg or between about 600 mg and about 800 mg and the ivermectin administrated at a dose of about 150 μg/kg. ### Claim 4 (depends on 2) The method of claim 2, wherein the favipiravir and the ivermectin are each administered in a plurality of doses over a plurality of days. ### Claim 5 (depends on 4) The method of claim 4, wherein the favipiravir is administered twice per day, wherein the doses of favipiravir administered on the first day are between about 1600 mg and about 1800 mg, and the doses of favipiravir administered on subsequent days are between about 600 and about 800 mg. ### Claim 6 (depends on 4) The method of claim 4, wherein the ivermectin is administered a daily, wherein a first dose of ivermectin is administered at least one day after a first dose of favipiravir. ### Claim 7 (depends on 4) The method of claim 4, wherein the favipiravir is administered on days 0 and 2-5 and the ivermectin is administered on days 1-10. ### Claim 8 (depends on 4) The method of claim 4, wherein the favipiravir is administered simultaneously with or immediately before or after administration of ivermectin. ### Claim 9 A method for treating a subject having an early-stage viral infection comprising administering to the subject a combination of an antiviral agent and an antiparasitic agent, wherein the early-stage viral infection is determined by a lateral flow assay, wherein the antiviral agent is selected from the group consisting of favipiravir, favipiravir-RTP, remdesivir, and molnupiravir and the antiparasitic agent is ivermectin, and wherein the virus is SARS-CoV-2. ### Claim 10 (depends on 9) The method of claim 9, wherein the antiviral agent is favipiravir. ### Claim 11 (depends on 10) The method of claim 10, wherein the favipiravir is administered at a dose of between about 1600 mg and about 1800 mg or between about 600 mg and about 800 mg and the ivermectin administrated at a dose of about 150 μg/kg. ### Claim 12 (depends on 9) The method of claim 9, wherein the sample is selected from the group consisting of saliva, blood, plasma, lymph, mucus, urine, feces, cells, and tissues.